Biomerica, Inc. (NASDAQ:BMRA) rose 9.9% Monday. Biomerica, last week, said it received a Notice of Allowance from Canadian Patent office for patent covering irritable bowel syndrome food sensitivity testing & treatment.
The company, out of Irvine, Calif., announced announced that the Canadian Patent Office has issued a notice of allowance for Biomerica’s patent application pertaining to the Company’s InFoods® diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from Irritable Bowel Syndrome ("IBS").
IBS is a chronic, often debilitating, functional gastrointestinal ("GI") disorder with symptoms that include abdominal pain, bloating, and altered bowel behaviors, such as constipation and/or diarrhea, or alternating between the two.
This allowed patent contains claims that broadly cover a method that enables physicians to identify patient-specific foods, such as egg, shrimp, broccoli, etc., that, when removed from the patient’s diet, may alleviate or improve an individual’s IBS symptoms, including constipation, diarrhea, bloating, severe cramping, pain, and indigestion.
Biomerica now has 11 patents issued worldwide of which two are granted in the U.S.. All of the Company’s InFoods® related issued and allowed patents expire in the year 2036 or later. The Company has a growing portfolio of international and US patent allowances and applications in prosecution related to the InFoods® IBS product, as well as multiple applications that cover the use of our InFoods® Technology in other diseases.
BMRA shares galloped 32 cents, or 6.5%, to $5.25.
